side effects of glp 1 after stopping Your guide to GLP-1 Long-term Success of GLP-1s Hinges

With World Health Organization (WHO) estimates indicating that 750 million adults worldwide are living with obesity, pharmaceutical companies have been developing innovative new drugs to tap into this lucrative market

References Ventura L, Arrizza L, Quaresima R, Capulli M (2022) Multidisciplinary investigation of an ancient renal stone in a mummy from Popoli, central Italy

In 2023, tirzepatide under the name Zepbound was FDA-approved for obesity as well, after showing ~48 lbs (~22%) mean weight loss over 72 weeks in a trial (SURMOUNT-2) ( [137] )

To obtain high-quality contrast images for disease diagnosis and monitoring the treatment response, a contrast agent is needed in MRI